The association of p53 mutations and p53 codon 72, Her 2 codon 655 and MTHFR C677T polymorphisms with breast cancer in Northern Greece

Cancer Lett. 2005 May 10;222(1):57-65. doi: 10.1016/j.canlet.2004.11.025.

Abstract

The aim of this study was to explore a possible association between p53 codon 72, Her 2 codon 655 and MTHFR C677T polymorphisms and breast cancer in Northern Greece. We examined 42 women with breast cancer and 51 controls. A total of 42 women with breast cancer as well as healthy controls were investigated and results showed that p53 codon 72 polymorphism is statistically significantly associated with breast cancer (OR for Arg/Arg to non-Arg/Arg was 6.66, P = 0.0001 at 95% CI 2.63-16.9), but not Her 2 and MTHFR polymorphisms are associated with breast cancer (OR for Ile/Ile to non-Ile/Ile was 1.33, P = 0.54 at 95% CI 0.52-3.38 and OR for T/T versus non-T/T was 1.07, P = 0.89 at 95% CI 0.35-3.25). All subjects were examined for p53 exons 5-8 mutations. Three novel sequence variations in exons 7 and 8 of TP53 gene were found in three patients. One of them induces an amino acid change at Ser 241Gly, the second is a silent mutation Gly244Gly, and the third one results in a premature stop codon 294 (Glu294stop) and a truncated p53 protein.

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Breast Neoplasms / epidemiology
  • Breast Neoplasms / genetics*
  • Case-Control Studies
  • Codon
  • DNA Mutational Analysis
  • DNA, Neoplasm / analysis*
  • Female
  • Genes, erbB-2 / genetics
  • Genes, p53 / genetics*
  • Genetic Predisposition to Disease
  • Genotype
  • Greece / epidemiology
  • Humans
  • Methylenetetrahydrofolate Reductase (NADPH2) / genetics
  • Middle Aged
  • Mutation
  • Polymorphism, Genetic*

Substances

  • Codon
  • DNA, Neoplasm
  • Methylenetetrahydrofolate Reductase (NADPH2)